Solid Tumors Clinical Trials

A listing of 48 Solid Tumors clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Solid Tumors

25 - 36 of 48

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 48 active clinical trials seeking participants for Solid Tumors research studies. The states with the highest number of trials for Solid Tumors participants are Texas, California, New York and Florida.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Research Study

Recruiting

Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Sinusitis

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Featured Trial

Stroke Clinical Study

Recruiting

A clinical study for people that suffer with Stroke

Conditions:

Stroke

Learn More

A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors

NCT06873789

Recruiting

This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/16/2025

Locations: The Angeles Clinic and Research Institute, Los Angeles, California +8 locations

Conditions: Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors

Learn More ›

Genomic Profiling in Cancer Patients

NCT01775072

Recruiting

The purpose of this study is to determine whether certain genes in cancer may be abnormal. When a gene is abnormal this is called a mutation. Most mutations in cancer cells are not inherited (passed down from parents) but happen after birth in the cancer itself. Most cancers have many mutations. Some of these mutations are important for the cancer cells to survive while others are not. The goal of this study is test cancer for certain mutations using leftover tumor tissue from a previous surgery... Read More

Gender:

ALL

Ages:

All

Trial Updated:

07/09/2025

Locations: St. Vincent (Data Collection Only), Bridgeport, Connecticut +18 locations

Conditions: Solid Tumors, Hematologic Cancers

Learn More ›

A Study of HS-20110 in Participants With Advanced Solid Tumors

NCT06892379

Recruiting

This is an open-label, multicenter study to evaluate the safety and tolerability of HS-20110 in participants with advanced solid malignant tumors

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/08/2025

Locations: BRCR Medical Center INC, Tamarac, Florida +2 locations

Conditions: Solid Tumors

Learn More ›

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

NCT06710132

Recruiting

The PROCEADE PanTumor study aims to investigate M9140 in multiple tumor types which express carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and it is therefore designed as a matrix study. This study aims to assess the antitumor activity, tolerability, safety, and pharmacokinetics (PK) of M9140 as monotherapy or in combination treatments in adult participants with locally advanced/metastatic CEACAM5 expressing tumors. There will be 3 substudies under this Master Protocol that... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/07/2025

Locations: University of California - Los Angeles - 300208353, Santa Monica, California +30 locations

University of California - Los Angeles - 300208353, Santa Monica, California

Providence Medical Foundation, Santa Rosa, California

Prisma Health Cancer Institute, ITOR, CRU, Greenville, South Carolina

Baptist Memorial Health Care -Memphis, Memphis, Tennessee

University of Texas M. D. Anderson Cancer Center - Partner, Houston, Texas

NEXT Virginia, Fairfax, Virginia

Mater Misericordiae Ltd - PARENT, South Brisbane, Not set

Macquarie University Hospital - PARENT, Sydney, Not set

Centre Georges François Leclerc - Unité de Phase I, Dijon cedex, Not set

Centre Oscar Lambret - cancerologie generale, Lille Cedex, Not set

Hôpital Saint-Antoine - Oncologie Médicale, Paris cedex 12, Not set

Hôpital Européen Georges Pompidou - Hématologie Oncologie, Paris Cedex 15, Not set

ICO - Site René Gauducheau - Service d'Oncologie medicale, Saint Herblain, Not set

Hôpital Foch - Service d'Oncologie Médicale, Suresnes Cedex, Not set

Hopital Rangueil - Service d'Oncologie médicale, Toulouse, Not set

National Cancer Center Hospital, Chuo-ku, Not set

Nara Medical University Hospital - Dept of Oncology, Kashihara-shi, Not set

Cancer Institute Hospital of JFCR, Koto-ku, Not set

Saiseikai Kumamoto Hospital - 300175708, Kumamoto-shi, Not set

Kurume University Hospital, Kurume-shi, Not set

Niigata Cancer Center Hospital - 300176282, Niigata-shi, Not set

NHO Hokkaido Cancer Center - 300175802, Sapporo-shi, Not set

Pusan National University Hospital, Busan, Not set

Kyungpook National University Chilgok Hospital, Daegu, Not set

Chonnam National University Hwasun Hospital, Hwasun-gun, Not set

Seoul National University Bundang Hospital, Seongnam, Not set

Asan Medical Center, Seoul, Not set

Korea University Guro Hospital, Seoul, Not set

Samsung Medical Center, Seoul, Not set

Seoul National University Hospital, Seoul, Not set

Severance Hospital, Yonsei University Health System - Division of Infectious Diseases, Seoul, Not set

Conditions: Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)

Learn More ›

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

NCT05836324

Recruiting

To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/27/2025

Locations: The Angeles Clinic and Research Institute, Los Angeles, California +35 locations

The Angeles Clinic and Research Institute, Los Angeles, California

Valkyrie Clinical Trials, Los Angeles, California

Dana Farber Cancer Institute, Boston, Massachusetts

Cancer and Hematology Centers of Western Michigan-Start Midwest, Grand Rapids, Michigan

Hackensack University Medical Center, Hackensack, New Jersey

Nyu Langone Health - Long Island Hospital, Mineola, New York

Laura and Isaac Perlmutter Cancer Center, New York, New York

University of Pennsylvania, Philadelphia, Pennsylvania

Lifespan Cancer Research Institute, Providence, Rhode Island

University of Texas Md Anderson Cancer Center, Houston, Texas

South Texas Accelerated Research Therapeutics, San Antonio, Texas

Rigshospitalet Uni of Hospital of Copenhagen, Copenhagen, Not set

Herlev Og Gentofte Hospital, Herlev, Not set

Odense University Hospital, Odense C, Not set

Vejle Hospital, Vejle, Not set

Centre Leon Berard, Lyon, Not set

Institut Gustave Roussy, Villejuif Cedex, Not set

Fondazione Irccs Istituto Nazionale Dei Tumori, Milano, Not set

Irccs Istituto Clinico Humanitas, Rozzano, Not set

Centro Ricerche Cliniche Di Verona, Verona, Not set

Kansai Medical University Hospital, Hirakata, Not set

The Cancer Institute Hospital of Jfcr, Koto-ku, Not set

National Cancer Center Hospital, Tokyo, Not set

Start Barcelona, Barcelona, Not set

Hospital General Universitario Vall D Hebron, Barcelona, Not set

Fundacion Jimenez Diaz University Hospital, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Centro Integral Oncologico Clara Campal, Madrid, Not set

Istituto Oncologico Della Svizzera Italiana, Bellinzona, Not set

Centre Hospitalier Universitaire Vaudois (Chuv), Lausanne, Not set

Kantonsspital St. Gallen, St. Gallen, Not set

Cambridge University Hospitals Nhs Foundation Trust, Cambridge, Not set

Guys and St Thomas Nhs Foundation Trust, London, Not set

Imperial College Healthcare Nhs Trust - Hammersmith Hospital, London, Not set

The Christie Nhs Foundation Trust Uk, Manchester, Not set

Freeman Hospital Newcastle Upon Tyne Foundation Nhs Trust, Newcastle Upon Tyne, Not set

Conditions: Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors

Learn More ›

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

NCT03175224

Recruiting

To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET * efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resis... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/24/2025

Locations: Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California +34 locations

Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California

Moffitt, Tampa, Florida

Dana Farber Cancer Institute, Boston, Massachusetts

University of North Carolina, Chapel Hill, North Carolina

Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania

University of Wisconsin, Madison, Wisconsin

St Vincents Hospital Melbourne, Melbourne, Not set

Cross Cancer Institute, Edmonton, Not set

McGill University Health Center - Research Institute, Montréal, Not set

Princess Margaret Hospital, Toronto, Not set

Cancer Care Manitoba, Winnipeg, Not set

CHRU de Brest - Hôpital Morvan, Brest, Not set

Centre Leon Berard, Lyon, Not set

Centre d'Essais Precoces en Cancerologie de Marseille, Marseille, Not set

Hopital Bichat - Claude Bernard - AP-HP, Paris, Not set

Gustave Roussy, Villejuif, Not set

Orszagos Koranyi Pulmonologiai Intezet, Budapest, Not set

Komarom-Esztergom Varmegyei Szent Borbala Korhaz, Tatabanya, Not set

IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola, Bologna, Not set

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Not set

Istituto Europeo di Oncologia, Milano, Not set

IRCCS Ospedale San Raffaele, Milan, Not set

Istituto Oncologico Veneto-I.R.C.C.S. - Ospedale Busonera, Padova, Not set

Private Medical Institution Euromedservice, Saint Petersburg, Not set

National Cancer Centre Singapore, Singapore, Not set

Hospital Germans Trias i Pujol, Badalona, Not set

Hospital Clinic Barcelona, Barcelona, Not set

Hospital del Mar, Barcelona, Not set

Institut Catala d'Oncologia - L'Hospitalet, Barcelona, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Instituto Valenciano de Oncologia, Valencia, Not set

National Taiwan University Hospital, Taipei City, Not set

University College London Hospital, London, Not set

The Christie NHS Foundation Trust, Manchester, Not set

Royal Marsden Hospital - Surrey, Surrey Quays, Not set

Conditions: Advanced Cancer, Renal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, NSCLC, Lung Cancer, Brain Tumor, Glioblastoma Multiforme, Solid Tumors, EGFR Gene Mutation, MET Amplification, HGF, Thyroid Cancer, Pancreatic Cancer, Colon Cancer, MET Alteration, MET Fusion, Exon 14 Skipping

Learn More ›

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors

NCT06431594

Recruiting

The goal of this study is to assess the safety and tolerability of GSK5733584. The study will also see how the levels of GSK5733584 change over time at different dose amount.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/19/2025

Locations: GSK Investigational Site, Lake Mary, Florida +46 locations

GSK Investigational Site, Lake Mary, Florida

GSK Investigational Site, Fairway, Kansas

GSK Investigational Site, Boston, Massachusetts

GSK Investigational Site, Detroit, Michigan

GSK Investigational Site, Grand Rapids, Michigan

GSK Investigational Site, Nashville, Tennessee

GSK Investigational Site, Dallas, Texas

GSK Investigational Site, West Valley City, Utah

GSK Investigational Site, Cipoletti Rio Negro, Not set

GSK Investigational Site, Ciudad de Buenos Aires, Not set

GSK Investigational Site, Rosario, Not set

GSK Investigational Site, Blacktown, New South Wales

GSK Investigational Site, Macquarie University, New South Wales

GSK Investigational Site, Leuven, Not set

GSK Investigational Site, Ottawa, Ontario

GSK Investigational Site, Toronto, Ontario

GSK Investigational Site, Montreal, Quebec

GSK Investigational Site, Helsinki, Not set

GSK Investigational Site, Tampere, Not set

GSK Investigational Site, Lyon Cedex 08, Not set

GSK Investigational Site, Saint Herblain, Not set

GSK Investigational Site, Villejuif cedex, Not set

GSK Investigational Site, Roma, Not set

GSK Investigational Site, Rozzano MI, Not set

GSK Investigational Site, Saitama, Not set

GSK Investigational Site, Shizuoka, Not set

GSK Investigational Site, Tokyo, Not set

GSK Investigational Site, Gyeonggi-do, Not set

GSK Investigational Site, Seoul, Not set

GSK Investigational Site, Amsterdam, Not set

GSK Investigational Site, Barcelona, Not set

GSK Investigational Site, COrdoba, Not set

GSK Investigational Site, Girona, Not set

GSK Investigational Site, Madrid, Not set

GSK Investigational Site, Pozuelo De AlarcOn Madr, Not set

GSK Investigational Site, Stockholm, Not set

GSK Investigational Site, Uppsala, Not set

GSK Investigational Site, Cambridge, Not set

GSK Investigational Site, London, Not set

Conditions: Solid Tumors, Neoplasms

Learn More ›

Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors

NCT06963281

Recruiting

The main purpose of this study is to evaluate the safety and tolerability of IBI3020 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RP2D) of IBI3020.

Gender:

ALL

Ages:

Between 18 years and 75 years

Trial Updated:

06/03/2025

Locations: Mayo Clinic - Arizona, Pheonix, Arizona +8 locations

Conditions: Solid Tumors

Learn More ›

A Study of ZL-1310 in Participants With Selected Solid Tumors

NCT06885281

Recruiting

A Phase Ib/II, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/02/2025

Locations: Zai Lab Site 2001, San Francisco, California +8 locations

Conditions: Solid Tumors

Learn More ›

S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

NCT05101070

Recruiting

The primary objective of Part A is to evaluate the safety and tolerability of S-531011 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of S-531011. The primary objective of Parts B and C is to evaluate the antitumor activity of S-531011 at the RP2D.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/22/2025

Locations: Angeles Clinic and Research Center, Los Angeles, California +7 locations

Conditions: Solid Tumors

Learn More ›

Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors

NCT06082960

Recruiting

The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-9911 when given alone or in combination with an anti-programmed cell death protein 1 (PD-1) monoclonal antibody in participants with advanced solid tumors. The primary objectives of this study are to: * Assess the safety and tolerability of GS-9911 as monotherapy and in combination with an anti-PD-1 monoclonal antibody in participants with advanced solid tumors * Identify the maximum tolerated dose (... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/13/2025

Locations: Smilow Cancer Hospital Phase 1 Unit, New Haven, Connecticut +5 locations

Conditions: Solid Tumors

Learn More ›

Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer

NCT06736379

Recruiting

The goal of this clinical trial is to assess the safety and tolerability of a virus replicon particle (VRP) encapsulated saRNA encoding IL-12 when injected into Squamous Cell Carcinomas in head and neck cancer patients. The main questions being addressed are: The safety and tolerability of intratumoral (IT) injections of VRP-encapsulated saRNA encoding IL-12 (VLPONC-01) The tumor response to IT injections of VLPONC-01 The tumor response due to the combination of IT injections of VLPONC-01 and... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/13/2025

Locations: Stanford University, Stanford, California

Conditions: Head and Neck Cancers- Squamous Cell, Head and Neck Cancer, Solid Tumors, HNSCC, SCC - Squamous Cell Carcinoma, SCCHN, Head Neck Cancer, Head and Neck Squamous Cell Cancer, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head and Neck, Squamous Cell Head and Neck Carcinoma, Oral Cavity, Oral Cavity Carcinoma

Learn More ›

25 - 36 of 48